Mistelihoidon näyttö kliinisissa tutkimukissa

Elämänlaatu

Tapausselostus: Astrozytooma Gr II 

159. Bouzek T. Misteltherapie bei Patienten mit Hirntumoren: 3 Kasuistiken. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2012;65(3):249-256. DOI: https://doi.org/10.14271/DMS-19966-DE

Mistelihoidon näyttö kliinisissä tutkimuksissa

Elämänlaatu

Loef M and Walach H.  Quality of Life in Cancer Patients Treated  with Mistletoe: a Systematic Review and Meta-analysis. Pre-print published at medRxivorg 2020. DOI: http://dx.doi.org/10.1101/19013177.

Poier D, Bussing A, Rodrigues Recchia D, Beerenbrock Y, Reif M, Nikolaou A, Zerm R, Gutenbrunner C and Kröz M. Influence of a Multimodal and Multimodal-Aerobic Therapy Concept on Health-Related Quality of Life in Breast Cancer Survivors. Integr Cancer Ther. 2019;18:1534735418820447.

Lyman G H, Greenlee H, Bohlke K, Bao T, DeMichele A M, Deng G E, Fouladbakhsh J M, Gil B, Hershman D L, Mansfield S, Mussallem D M, Mustian K M, Price E, Rafte S and Cohen L. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol, 2018;36:2647-2655. DOI: 10.1200/JCO.2018.79.2721

Kienle G S, Mussler M, Fuchs D and Kiene H. The Subjective Dimension of Integrative Cancer Care: A Qualitative Study Exploring the Perspectives, Themes, and Observations of Experienced Doctors from the Area of Anthroposophic Medicine. Explore (NY), 2018;14:342-351. DOI: 10.1016/j.explore.2018.03.007

Kröz M, Büssing A, Reif M, Pranga D, Schad F, Zerm R, Matthes H and Girke M. (2016).Besteht eine Indikation für die Misteltherapie in der Behandlung von Cancer-related Fatigue und Insomnie bei Krebspatienten? –  Ein Review In: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4 Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S.287-298.

Kienle G S, Mussler M, Fuchs D and Kiene H. Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors. Evid Based Complement Alternat Med, 2016;2016:4628287. DOI: 10.1155/2016/4628287

Evans M, Bryant S, Huntley AL and Feder G. Cancer patients' experiences of using mistletoe (Viscum album): a qualitative systematic review and synthesis. The Journal of Alternative and Complementary Medicine (New York, N.Y.) 2016;22(2):134–144.

Tröger W, Zdrale Z, Tisma N and Matijasevic M. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evidence-Based Complementary and Alternative Medicine, 2014;2014:01. Sep. DOI: 10.1155/2014/430518

Tröger W, Galun D, Reif M, Schumann A, Stankovic N and Milicevic M. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int, 2014;111:493-502, 433 p following 502. DOI: 10.3238/arztebl.2014.0493

Brandenburger M, Simoes-Wüst A P, Rostock M, Rist L and Saller R. Quality-of-life of cancer patients during mistletoe therapy - An exploratory study with the additional use of questionnaires (Lebensqualität von Krebspatienten während der Misteltherapie - Eine explorative Studie mit dem zusätzlichen Einsatz von Fragebögen). In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors. Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E and Haim N. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer, 2013;49:1058-1064 DOI: 10.1016/j.ejca.2012.11.007

Kim K-C, Yook J-H, Eisenbraun J, Kim B-S and Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma–a randomized, controlled pilot study. BMC Complementary and Alternative Medicine, 2012;12:172 

Büssing A, Raak C and Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med, 2012;2012:219402. DOI: 10.1155/2012/219402

Eisenbraun J, Scheer R, Kroz M, Schad F and Huber R. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine, 2011;18:151-157. DOI: 10.1016/j.phymed.2010.06.013

Kienle G S and Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther, 2010;9:142-157. DOI: 10.1177/1534735410369673.

Tröger W, Jezdic S, Zdrale Z, Tisma N, Hamre H J and Matijasevic M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer 2009;3:35-45.

Melzer J, Iten F, Hostanska K and Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed, 2009;16:217-226.doi:10.1159/000226249. DOI: 10.1159/000226249.

Kröz M, Büssing A, von Laue B H, Reif M, Feder G, Schad F, Girke M and Matthes H. Reliability and validity of a new scale on internal coherence (ICS) of cancer patients. Health Qual Life Outcomes, 2009;7:59. DOI:10.1186/1477-7525-7-59

Engdal S and Nilsen O G. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res, 2009;23:906-912. DOI: 10.1002/ptr.2750

Büssing A, Girke M, Heckmann C, Schad F, Ostermann T and Kröz M. Validation of the self-regulation questionnaire as a measure of health in quality of life research. Eur J Med Res 2009;14:223-227

Friedel W E, Matthes H, Bock P R and Zanker K S. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009;7:137-145

Horneber M A, Bueschel G, Huber R, Linde K and Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev, 2008:CD003297. DOI: 10.1002/14651858.CD003297.pub22

Loewe-Mesch A, Kuehn J J, Borho K, Abel U, Bauer C, Gerhard I, Schneeweiss A, Sohn C, Strowitzki T and v Hagens C. [Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolerability]. Forsch Komplementmed, 2008;15:22-30. DOI: 10.1159/000112860 

Kröz M, Zerm R, Reif M, von Laue B H, Schad F, Bussing A, Bartsch C, Feder G and Girke M. Validation of the German version of the Cancer Fatigue Scale (CFS-D). Eur J Cancer Care (Engl), 2008;17:33-41. DOI: 10.1111/j.1365-2354.2007.00799.x

Lange-Lindberg A M, Velasco Garrido M and Busse R. Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Technol Assess 2006;2:Doc18

Piao B K, Wang Y X, Xie G R, Mannsmann U, Matthes H, Beuth J and Lin H S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research 2004;24:303-310

 

Grossarth-Maticek R, Kiene H, Baumgartner S M and Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001;7:57-66, 68-72, 74-56 passim

Sivut päivitetty 7-10-2020

© Suomen Antroposofisen lääketieteen lääkäriyhdistys (SALLY) ry

© Mistelikuvat/Mistletoe-Images: Jürg Buess  – Institut Hiscia, Arlesheim (CH)